C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both? A systematic evaluation in pediatric ulcerative colitis

Journal of Crohn's and Colitis

Volumn 5, Issue 5, 2011, Pages 423-429

  Turner, Dan ^a   Mack, David R ^b   Hyams, Jeffrey ^c   LeLeiko, Neal ^d   Otley, Anthony ^e   Markowitz, James ^f   Kasirer, Yair ^a   Muise, Aleixo ^g   Seow, Cynthia H ^h   Silverberg, Mark S ⁱ   Crandall, Wallace ^j   Griffiths, Anne M ^g  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^c Farmington   (United States)

^d HASBRO CHILDREN'S HOSPITAL   (United States)

^e IWK HEALTH CENTRE   (Canada)

^f New Hyde Park   (United States)

^g HOSPITAL FOR SICK CHILDREN   (Canada)

^h UNIVERSITY OF CALGARY   (Canada)

ⁱ MOUNT SINAI HOSPITAL   (Canada)

^j NATIONWIDE CHILDREN S HOSPITAL   (United States)

more..

Author keywords

C reactive protein; Disease activity; Erythrocyte sedimentation rate; Pediatrics; Ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN;

ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA COLLECTION METHOD; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE SEVERITY; ENDOSCOPY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LABORATORY TEST; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SCHOOL CHILD; ULCERATIVE COLITIS;

ADOLESCENT; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COLITIS, ULCERATIVE; FEMALE; HUMANS; INFANT; LONGITUDINAL STUDIES; MALE; MULTIVARIATE ANALYSIS; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SIGMOIDOSCOPY;

EID: 80053130561     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.05.003     Document Type: Article

References (37)

1. Harries A.D., Fitzsimons E., Fifield R., Dew M.J., Rhoades J. Platelet count: a simple measure of activity in Crohn's disease. Br Med J (Clin Res Ed) 1983, 286:1476.
2. Solem C.A., Loftus E.V., Tremaine W.J., Harmsen W.S., Zinsmeister A.R., Sandborn W.J. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005, 11:707-712.
3. Mack D.R., Langton C., Markowitz J., LeLeiko N., Griffiths A., Bousvaros A., Evans J., Kugathasan S., Otley A., Pfefferkorn M., Rosh J., Mezoff A., Moyer S., Oliva-Hemker M., Rothbaum R., Wyllie R., delRosario J.F., Keljo D., Lerer T., Hyams J. Laboratory values for children with newly diagnosed inflammatory bowel disease. Pediatrics 2007, 119:1113-1119.
4. Turner D., Otley A.R., Mack D., Hyams J., de Bruijne J., Uusoue K., Walters T.D., Zachos M., Mamula P., Beaton D.E., Steinhart A.H., Griffiths A.M. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007, 133:423-432.
5. Turner D., Mack D., Leleiko N., Walters T.D., Uusoue K., Leach S.T., Day A.S., Crandall W., Silverberg M.S., Markowitz J., Otley A.R., Keljo D., Mamula P., Kugathasan S., Hyams J., Griffiths A.M. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology 2010, 138:2282-2291.
6. Turner D., Walsh C.M., Benchimol E.I., Mann E.H., Thomas K.E., Chow C., McLernon R.A., Walters T.D., Swales J., Steinhart A.H., Griffiths A.M. Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy. Gut 2008, 57:331-338.
7. Beattie R.M., Nicholls S.W., Domizio P., Williams C.B., Walker-Smith J.A. Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis. J Pediatr Gastroenterol Nutr 1996, 22:373-379.
8. Mary J.Y., Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989, 30:983-989.
9. Gomes P., du Boulay C., Smith C.L., Holdstock G. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986, 27:92-95.
10. Linskens R.K., van Bodegraven A.A., Schoorl M., Tuynman H.A., Bartels P. Predictive value of inflammatory and coagulation parameters in the course of severe ulcerative colitis. Dig Dis Sci 2001, 46:644-648.
11. Consigny Y., Modigliani R., Colombel J.F., Dupas J.L., Lemann M., Mary J.Y. A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm Bowel Dis 2006, 12:551-557.
12. Xiang J.Y., Ouyang Q., Li G.D., Xiao N.P. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J Gastroenterol 2008, 14:53-57.
13. Vermeire S., Van Assche G., Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys?. Gut 2006, 55:426-431.
14. Lewis J.D. C-reactive protein: anti-placebo or predictor of response. Gastroenterology 2005, 129:1114-1116.
15. Koelewijn C.L., Schwartz M.P., Samsom M., Oldenburg B. C-reactive protein levels during a relapse of Crohn's disease are associated with the clinical course of the disease. World J Gastroenterol 2008, 14:85-89.
16. Cabrera-Abreu J.C., Davies P., Matek Z., Murphy M.S. Performance of blood tests in diagnosis of inflammatory bowel disease in a specialist clinic. Arch Dis Child 2004, 89:69-71.
17. Beattie R.M., Walker-Smith J.A., Murch S.H. Indications for investigation of chronic gastrointestinal symptoms. Arch Dis Child 1995, 73:354-355.
18. Barnes B.H., Borowitz S.M., Saulsbury F.T., Hellems M., Sutphen J.L. Discordant erythrocyte sedimentation rate and C-reactive protein in children with inflammatory bowel disease taking azathioprine or 6-mercaptopurine. J Pediatr Gastroenterol Nutr 2004, 38:509-512.
19. Landis J.R., Koch G.G. The measurement of observer agreement for categorical data. Biometrics 1977, 33:159-174.
20. Prantera C., Davoli M., Lorenzetti R., Pallone F., Marcheggiano A., Iannoni C., Mariotti S. Clinical and laboratory indicators of extent of ulcerative colitis. Serum C-reactive protein helps the most. J Clin Gastroenterol 1988, 10:41-45.
21. Griffiths A.M. Specificities of inflammatory bowel disease in childhood. Best Pract Res Clin Gastroenterol 2004, 18:509-523.
22. Moum B., Ekbom A., Vatn M.H., Elgjo K. Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time. Am J Gastroenterol 1999, 94:1564-1569.
23. Vermeire S., Van Assche G., Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004, 10:661-665.
24. Schreiber S., Rutgeerts P., Fedorak R.N., Khaliq-Kareemi M., Kamm M.A., Boivin M., Bernstein C.N., Staun M., Thomsen O.O., Innes A. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005, 129:807-818.
25. Sandborn W.J., Feagan B.G., Radford-Smith G., Kovacs A., Enns R., Innes A., Patel J. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut 2004, 53:1485-1493.
26. Rutgeerts P., Colombel J.F., Enns J. Subanalysis from a phase 3 study on the evaluation of natalizumab in active Crohn's disease. Gut 2003, 52:A239.
27. Macfarlane P.I., Miller V., Wells F., Richards B. Laboratory assessment of disease activity in childhood Crohn's disease and ulcerative colitis. J Pediatr Gastroenterol Nutr 1986, 5:93-96.
28. Sachar D.B., Smith H., Chan S., Cohen L.B., Lichtiger S., Messer J. Erythrocytic sedimentation rate as a measure of clinical activity in inflammatory bowel disease. J Clin Gastroenterol 1986, 8:647-650.
29. Moran A., Jones A., Asquith P. Laboratory markers of colonoscopic activity in ulcerative colitis and Crohn's colitis. Scand J Gastroenterol 1995, 30:356-360.
30. Buckell N.A., Lennard-Jones J.E., Hernandez M.A., Kohn J., Riches P.G., Wadsworth J. Measurement of serum proteins during attacks of ulcerative colitis as a guide to patient management. Gut 1979, 20:22-27.
31. Lindgren S.C., Flood L.M., Kilander A.F., Lofberg R., Persson T.B., Sjodahl R.I. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998, 10:831-835.
32. Travis S.P., Farrant J.M., Ricketts C., Nolan D.J., Mortensen N.M., Kettlewell M.G., Jewell D.P. Predicting outcome in severe ulcerative colitis. Gut 1996, 38:905-910.
33. Benazzato L., D'Inca R., Grigoletto F., Perissinotto E., Medici V., Angriman I., Sturniolo G.C. Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment. Dig Liver Dis 2004, 36:461-466.
34. Ho G.T., Mowat C., Goddard C.J., Fennell J.M., Shah N.B., Prescott R.J., Satsangi J. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 2004, 19:1079-1087.
35. Bitton A., Peppercorn M.A., Antonioli D.A., Niles J.L., Shah S., Bousvaros A., Ransil B., Wild G., Cohen A., Edwardes M.D., Stevens A.C. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001, 120:13-20.
36. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987, 317:1625-1629.
37. Lichtiger S., Present D.H., Kornbluth A., Gelernt I., Bauer J., Galler G., Michelassi F., Hanauer S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994, 330:1841-1845.